Ivonescimab (SMT112, AK112), a first-in-class, humanized, tetravalent PD-1/VEGF bispecific monoclonal antibody, being internally developed by Akeso Biopharma (a China-based commercial-stage biopharmaceutical company), has shown exceptional results in
Is Merck ready to face the looming patent cliff? Impact of Inflation Reduction Act (IRA) on Keytruda Inflation Reduction Act (IRA) was passed in 2022
With the recent approval of the first two interchangeable biosimilars to Amgen’s PROLIA® and XGEVA® by the US FDA in March 2024, the overall count
A Detailed Analysis of Patent Term Extensions Expiring in the U.S. between 2023-2028 A drug manufacturer can enjoy monopoly in the market till 20 years
The Steepest Patent Cliff in Order Big pharma companies focusing on anti-diabetic drugs are bracing themselves for the steepest patent cliff this decade. With Eli
